Terns Pharmaceuticals, Inc. Logo

Terns Pharmaceuticals, Inc.

Clinical-stage biopharma developing small-molecule drugs for oncology and obesity.

TERN | US

Overview

Corporate Details

ISIN(s):
US8808811074
LEI:
Country:
United States of America
Address:
1065 EAST HILLSDALE BLVD., SUITE 100, 94404 FOSTER CITY

Description

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops a portfolio of small-molecule product candidates for serious diseases, with a focus on oncology and obesity. The company's strategy is to innovate upon de-risked, clinically validated mechanisms of action to create therapies with superior efficacy, safety, and convenience profiles. Its lead product candidate, TERN-701, is an oral, allosteric BCR-ABL inhibitor in development for the treatment of chronic myeloid leukemia (CML). Terns aims to address significant unmet medical needs by improving upon existing treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Terns Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Terns Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Terns Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SPRUCE BIOSCIENCES, INC. Logo
A clinical-stage biopharma developing therapies for underserved neurological disorders.
United States of America
SPRB
Stayble Therapeutics AB Logo
Develops treatments for chronic pain originating from spinal disc conditions.
Sweden
STABL
STCUBE Logo
Develops immuno-oncology therapies targeting novel immune checkpoints for cancer.
South Korea
052020
StemRIM Inc. Logo
Develops regenerative medicine that uses the body's own stem cells for tissue repair.
Japan
4599
Surrozen, Inc./DE Logo
Develops drug candidates to selectively modulate the Wnt pathway for tissue repair.
United States of America
SRZN
SyntekaBio,Inc. Logo
An AI-driven drug discovery company using supercomputing to accelerate development.
South Korea
226330
Tango Therapeutics, Inc. Logo
A clinical-stage biotech developing precision oncology medicines via synthetic lethality.
United States of America
TNGX
Taysha Gene Therapies, Inc. Logo
Clinical-stage company developing AAV-based gene therapies for severe CNS diseases.
United States of America
TSHA
Tectonic Therapeutic, Inc. Logo
Clinical-stage biotech developing biologics targeting G-Protein Coupled Receptors (GPCRs).
United States of America
TECX
Telomir Pharmaceuticals, Inc. Logo
Pre-clinical pharma company developing a small molecule for aging and chronic disease.
United States of America
TELO

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.